Assessment of circulating tumor DNA in pediatric solid tumors: The promise of liquid biopsies

Circulating tumor DNA can be detected in the blood and body fluids of patients using ultrasensitive technologies, which have the potential to improve cancer diagnosis, risk stratification, noninvasive tumor profiling, and tracking of treatment response and disease recurrence. As we begin to apply “l...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric blood & cancer 2019-05, Vol.66 (5), p.e27595-n/a
Main Authors: Abbou, Samuel D., Shulman, David S., DuBois, Steven G., Crompton, Brian D.
Format: Article
Language:English
Subjects:
Biomarkers, Tumor - analysis
Biomarkers, Tumor - genetics
Biopsy
Blood circulation
Body fluids
Cancer
Children
circulating tumor DNA
Circulating Tumor DNA - analysis
Circulating Tumor DNA - genetics
Deoxyribonucleic acid
digital PCR
DNA
Feasibility studies
Health risks
Hematology
Humans
Liquid Biopsy
Medical treatment
Neoplasms - blood
Neoplasms - diagnosis
Neoplasms - genetics
next‐generation sequencing
Oncology
pediatric cancer
Pediatrics
Precision Medicine
Solid tumors
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Circulating tumor DNA can be detected in the blood and body fluids of patients using ultrasensitive technologies, which have the potential to improve cancer diagnosis, risk stratification, noninvasive tumor profiling, and tracking of treatment response and disease recurrence. As we begin to apply “liquid biopsy” strategies in children with cancer, it is important to tailor our efforts to the unique genomic features of these tumors and address the technical and logistical challenges of integrating biomarker testing. This article reviews the literature demonstrating the feasibility of applying liquid biopsy to pediatric solid malignancies and suggests new directions for future studies.
ISSN:1545-5009
1545-5017
DOI:10.1002/pbc.27595